Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

Health Canada lists Erelzi 25 mg etanercept shortage as Tier 3

Sandoz reports a manufacturing disruption affecting Erelzi 25 mg/0.5 mL prefilled syringes. The company estimates the shortage will end Feb. 12, 2027.

2 min read4 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
A disposable syringe, shown for illustration. Photo by Friedrich Haag via Wikimedia Commons (CC BY-SA 4.0). Image source Image source
In this article & details

Article details

Published
Nov 16, 2026
Reading time
2 min read
Categories
Drug Shortages
Jurisdiction
National
Sources cited
4
All news

Health Canada classified a shortage of 25 mg/0.5 mL etanercept injection as Tier 3 on Nov. 12. Sandoz Canada reports a manufacturing disruption affecting Erelzi 25 mg prefilled syringes, DIN 02462877. Its Nov. 13 report lists an active shortage and an estimated end date of Feb. 12, 2027. Health Canada designation · Sandoz shortage report

The designation identifies the 25 mg syringe

Health Canada’s Drug Product Database identifies the affected presentation as a single-use prefilled syringe for subcutaneous injection. Erelzi is a biosimilar of etanercept, used for conditions including rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. Other Erelzi presentations include a 50 mg prefilled syringe and a 50 mg auto-injector. The federal designation specifies the 25 mg/0.5 mL presentation. Canadian product record · B.C. PharmaCare decision summary

Tier 3 signals a potentially serious supply impact

Health Canada uses Tier 3 for shortages that could have the greatest effect on the Canadian drug supply and health system. Its assessment considers how necessary the drug is and how readily supplies or alternatives can be found. The Canadian Rheumatology Association and Canadian Pharmacists Association were among the organizations represented in the etanercept assessment. Sandoz’s report is the source for its projected end date and later supply updates. Tier 3 criteria and committee · Latest manufacturer status

References

  1. Tier 3 drug shortages — Health Canada, Etanercept determination, Nov. 12, 2026
  2. Drug Shortage Report for ERELZI — Sandoz Canada Incorporated, Health Product Shortages Canada, Report 295430, updated Nov. 13, 2026
  3. Product information: ERELZI — Health Canada Drug Product Database, DIN 02462877
  4. Erelzi (etanercept): Drug decision summary — British Columbia PharmaCare, Background on strengths and approved indications

Discussion

0 comments

Join the discussion. Anyone can read the comments. To comment, log in or create a free individual account.

No comments yet.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.